Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 3Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 119Squamous Cell Carcinoma of Head and Neck 60Melanoma 57Parkinson Disease 4, Autosomal Dominant Lewy Body 46Lung Neoplasms 45Triple Negative Breast Neoplasms 44Neoplasm Metastasis 42Breast Neoplasms 40Neoplasms 36Colorectal Neoplasms 31Head and Neck Neoplasms 27Endometrial Neoplasms 26Carcinoma, Renal Cell 26Ovarian Neoplasms 23Carcinoma, Transitional Cell 22Urinary Bladder Neoplasms 20Stomach Neoplasms 15Carcinoma 14Pancreatic Neoplasms 13Uterine Cervical Neoplasms 12Recurrence 12Esophageal Neoplasms 12Sarcoma 11Hodgkin Disease 11Brain Neoplasms 11Carcinoma, Squamous Cell 10Cholangiocarcinoma 9Carcinoma, Hepatocellular 9Skin Neoplasms 8Esophageal Squamous Cell Carcinoma 8

Interventions

Capecitabine 22Oxaliplatin 19Fluorouracil 16Radiotherapy 11Leucovorin 10Cetuximab 9Nivolumab 7Bevacizumab 6sintilimab 5Specimen Handling 5Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Irinotecan 5Folfox protocol 5trifluridine tipiracil drug combination 4pembrolizumab 4Surgical Procedures, Operative 4encorafenib 3X-Rays 3Trastuzumab 3Surveys and Questionnaires 3Sigmoidoscopy 3Radiation 3Pemetrexed 3Gemcitabine 3Endoscopy 3Control Groups 3Consolidation Chemotherapy 3Cisplatin 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Rectal Neoplasms × pembrolizumab × 90 days × Clear all
NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Pfizer

Phase 1 Terminated
30 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Pfizer

Phase 1 Recruiting
330 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT05217446 2026-04-07

SEAMARK

Pfizer

Phase 2 Active not recruiting
107 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡